Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Capricor Therapeutics (CAPR) Other Accumulated Expenses (2022 - 2025)

Historic Other Accumulated Expenses for Capricor Therapeutics (CAPR) over the last 4 years, with Q3 2025 value amounting to $2.6 million.

  • Capricor Therapeutics' Other Accumulated Expenses rose 2612155.0% to $2.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.6 million, marking a year-over-year increase of 2612155.0%. This contributed to the annual value of $435712.0 for FY2024, which is 425712.0% up from last year.
  • According to the latest figures from Q3 2025, Capricor Therapeutics' Other Accumulated Expenses is $2.6 million, which was up 2612155.0% from $1.4 million recorded in Q2 2025.
  • In the past 5 years, Capricor Therapeutics' Other Accumulated Expenses registered a high of $2.6 million during Q3 2025, and its lowest value of $10000.0 during Q4 2023.
  • For the 4-year period, Capricor Therapeutics' Other Accumulated Expenses averaged around $485865.9, with its median value being $54706.0 (2022).
  • As far as peak fluctuations go, Capricor Therapeutics' Other Accumulated Expenses tumbled by 8879.35% in 2023, and later skyrocketed by 2612155.0% in 2025.
  • Capricor Therapeutics' Other Accumulated Expenses (Quarter) stood at $89234.0 in 2022, then plummeted by 88.79% to $10000.0 in 2023, then soared by 4257.12% to $435712.0 in 2024, then soared by 501.81% to $2.6 million in 2025.
  • Its Other Accumulated Expenses stands at $2.6 million for Q3 2025, versus $1.4 million for Q2 2025 and $201681.0 for Q1 2025.